Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China [Yahoo! Finance]
Adlai Nortye Ltd. - American Depositary Shares (ANL)
Company Research
Source: Yahoo! Finance
Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into an exclusive licensing agreement with ASK Pharm for its proprietary pan-RAS (ON) inhibitor AN9025. Under the terms of the agreement, ASK Pharm will obtain exclusive rights to develop, manufacture, and commercialize AN9025 in mainland China, Hong Kong and Macao (the “Licensed Territory”). Adlai Nortye will retain worldwide rights to the compound excluding the Licensed Territory. Adlai Nortye is eligible to receive total consideration of up to RMB 1.6 billion (approximately USD 230 million), including an upfront payment and near-term milestone payments exceeding USD 20 million, plus tiered royalties ranging from a high single-digit to mid-teens percentage of net product sales in the Licensed Territory. Mr. Jingfei Ma, Director and General Manager of ASK Pharm, stated: “This partnership marks a pivotal milestone in our strategic innovati
Show less
Read more
Impact Snapshot
Event Time:
ANL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANL alerts
High impacting Adlai Nortye Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ANL
News
- Adlai Nortye (ANL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ANL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "hold".MarketBeat
- Adlai Nortye (NASDAQ:ANL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.MarketBeat
- Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS MutationsGlobeNewswire
- Adlai Nortye Announces $140.0 Million Private Placement Equity Financing [Yahoo! Finance]Yahoo! Finance
- Adlai Nortye Announces $140.0 Million Private Placement Equity FinancingGlobeNewswire
ANL
Sec Filings
- 3/10/26 - Form F-3
- 2/12/26 - Form 6-K
- 2/11/26 - Form SCHEDULE
- ANL's page on the SEC website